PlainRecalls
FDA Drug Critical Class I Ongoing

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

Reported: February 5, 2025 Initiated: December 23, 2024 #D-0210-2025

Product Description

Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.

Reason for Recall

Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Details

Recalling Firm
Astellas Pharma US Inc.
Units Affected
3,500 30-count bottles
Distribution
Nationwide in the USA
Location
Northbrook, IL

Frequently Asked Questions

What product was recalled?
Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73.. Recalled by Astellas Pharma US Inc.. Units affected: 3,500 30-count bottles.
Why was this product recalled?
Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules
Which agency issued this recall?
This recall was issued by the FDA Drug on February 5, 2025. Severity: Critical. Recall number: D-0210-2025.